Search

Your search keyword '"Cecchini, Michael"' showing total 53 results
Start Over Author "Cecchini, Michael" Publisher american association for cancer research (aacr)
53 results on '"Cecchini, Michael"'

1. Abstract A072: Keratin 17-signature for stratification of chemotherapy in pancreatic adenocarcinoma

Author

Chowdhury, Sumedha, primary, Yugawa, Deanne, additional, Tseng, Robert, additional, Mejia, Mauricio, additional, Lacy, Jill, additional, Patel, Timil, additional, Escobar-Hoyos, Luisa, additional, Shroyer, Kenneth, additional, Cai, Guoping, additional, Robert, Marie, additional, Cecchini, Michael, additional, Kunstman, John, additional, Farrell, James, additional, and Johung, Kimberly, additional

Published
2024
Full Text
View/download PDF

2. Abstract B117: Phase 1 study of CM24 in combination with nivolumab in patients with advanced pancreatic cancer - Survival, potential biomarker and effect on neutrophil extracellular traps (NETs)

Author

Borazanci, Erkut, primary, Pant, Shubham, additional, Perets, Ruth, additional, Golan, Talia, additional, Al Hallak, Mohammed Najeeb, additional, Cecchini, Michael, additional, Maierson, Tomer, additional, David, Hava Ben, additional, Schickler, Michael, additional, and Reuveni, Hadas, additional

Published
2024
Full Text
View/download PDF

3. Abstract A002: A phase II study of peri-operative modified FOLFIRINOX in localized pancreatic ductal adenocarcinoma (PDAC)

Author

Cecchini, Michael, primary, Salem, Ronald, additional, Robert, Marie, additional, Czerniak, Suzanne, additional, Rajaei, Moein, additional, Townsend, Jeffrey, additional, Blaha, Ondrej, additional, Zelterman, Daniel, additional, Thumar, Jaykumar, additional, Kortmansky, Jeremy, additional, Zaheer, Wajih, additional, Fischbach, Neal, additional, Persico, Justin, additional, Stein, Stacey, additional, Khan, Sajid, additional, Cha, Charles, additional, Billingsley, Kevin, additional, Kunstman, John, additional, Chowdhury, Sumedha, additional, Tseng, Robert, additional, Mauricio, Carlos, additional, Yugawa, Deanne, additional, Escobar-Hoyos, Luisa, additional, Johung, Kimberly, additional, Wiess, Christina, additional, Spickard, Erik, additional, Aushev, Vasily N., additional, Laliotis, George, additional, Jurdi, Adham, additional, Liu, Minetta C., additional, and Lacy, Jill, additional

Published
2024
Full Text
View/download PDF

4. Supplementary Figure 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

5. TABLE 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Methods 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

8. Data from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

11. TABLE 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 4 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 3 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 4 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

15. TABLE 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Table 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 3 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

19. TABLE 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Methods 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

21. Data from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

23. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., additional, Wei, Wei, additional, Sklar, Jeffrey, additional, Lacy, Jill, additional, Zhong, Minghao, additional, Kong, Yong, additional, Zhao, Hongyu, additional, DiPalermo, Jassim, additional, Devine, Lesley, additional, Stein, Stacey M., additional, Kortmansky, Jeremy, additional, Johung, Kimberly L., additional, Bindra, Ranjit S., additional, LoRusso, Patricia, additional, and Schalper, Kurt A., additional

Published
2023
Full Text
View/download PDF

24. Supplementary Table 1 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer

Author

Cecchini, Michael, primary, Zhang, Janie Y., primary, Wei, Wei, primary, Sklar, Jeffrey, primary, Lacy, Jill, primary, Zhong, Minghao, primary, Kong, Yong, primary, Zhao, Hongyu, primary, DiPalermo, Jassim, primary, Devine, Lesley, primary, Stein, Stacey M., primary, Kortmansky, Jeremy, primary, Johung, Kimberly L., primary, Bindra, Ranjit S., primary, LoRusso, Patricia, primary, and Schalper, Kurt A., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 2 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

26. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, additional, Wei, Wei, additional, Hafez, Navid, additional, Pilat, Mary Jo, additional, Boerner, Scott A., additional, Durecki, Diane E., additional, Eder, Joseph P., additional, Schalper, Kurt A., additional, Chen, Alice P., additional, and LoRusso, Patricia, additional

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 3 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 2 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Table 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure 3 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Methods 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Methods 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 2 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

37. Data from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A., primary, Durecki, Diane E., primary, Eder, Joseph P., primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

38. Data from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure 2 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 2 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Methods 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 2 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 3 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Table 2 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Table 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

Author

Cecchini, Michael, primary, Walther, Zenta, primary, Wei, Wei, primary, Hafez, Navid, primary, Pilat, Mary Jo, primary, Boerner, Scott A, primary, Durecki, Diane E, primary, Eder, Joseph P, primary, Schalper, Kurt A., primary, Chen, Alice P., primary, and LoRusso, Patricia, primary

Published
2023
Full Text
View/download PDF

49. Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations

Author

Yap, Timothy A., primary, Yadav, Siddhartha, additional, Herzberg, Benjamin, additional, Carneiro, Benedito A., additional, Fontana, Elisa, additional, Højgaard, Martin, additional, Pishvaian, Michael J., additional, Plummer, Ruth, additional, Werner, Theresa L., additional, Sahai, Vaibhav, additional, Lheureux, Stephanie, additional, Lee, Elizabeth K., additional, Mettu, Niharika B., additional, Cote, Gregory M., additional, Schonhoft, Joseph D., additional, Rimkunas, Victoria, additional, Silverman, Ian M., additional, Wainszelbaum, Marisa, additional, Peltz, Gerson, additional, Fretland, Adrian J., additional, Fei, Kezhen, additional, Ulanet, Danielle, additional, Kim, Insil, additional, Koehler, Maria, additional, Rosen, Ezra, additional, and Cecchini, Michael, additional

Published
2023
Full Text
View/download PDF

50. Abstract CT170: A phase 1/2 study of olaparib in combination with ramucirumab in metastatic gastric and gastroesophageal junction adenocarcinoma (GEJ)

Author

Cecchini, Michael, primary, Chao, Joseph, additional, Shyr, Yu, additional, Cleary, James, additional, Uboha, Nataliya, additional, Cho, May, additional, Shields, Anthony, additional, Pant, Shubham, additional, Goff, Laura, additional, Spencer, Kristin, additional, Kim, Edward, additional, Hsu, Chih-Yuan, additional, Stein, Stacey, additional, Thumar, Jaykumar, additional, Kortmansky, Jeremy, additional, Kunstman, John, additional, LoRusso, Patricia, additional, Ivy, Percy, additional, and Lacy, Jill, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results